Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in ...

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the ...

Fast-tracked psychedelics hit a wall: why the FDA’s pause on psilocybin is an important check to ensure safety, rigor, and long-term evidence before the drugs reach patients.

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...

COMPASS Pathways plc (CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the ...